![Page 1: Acute Pain Management in the Hospital Settingmchodessa.com/wp-content/uploads/2017/10/... · antagonist drug or abrupt dose reduction or discontinuation Physical dependence •A behavioral](https://reader034.vdocument.in/reader034/viewer/2022050122/5f52ade31e7d9169ce21b016/html5/thumbnails/1.jpg)
Acute Pain Management in the
Hospital SettingAlexandra Phan, PharmD
PGY-1 Pharmacy Practice Resident
Medical Center Hospital
Odessa, TX
![Page 2: Acute Pain Management in the Hospital Settingmchodessa.com/wp-content/uploads/2017/10/... · antagonist drug or abrupt dose reduction or discontinuation Physical dependence •A behavioral](https://reader034.vdocument.in/reader034/viewer/2022050122/5f52ade31e7d9169ce21b016/html5/thumbnails/2.jpg)
What is Pain?
• “An unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage”
• “Whatever the patient says it is”
2
![Page 3: Acute Pain Management in the Hospital Settingmchodessa.com/wp-content/uploads/2017/10/... · antagonist drug or abrupt dose reduction or discontinuation Physical dependence •A behavioral](https://reader034.vdocument.in/reader034/viewer/2022050122/5f52ade31e7d9169ce21b016/html5/thumbnails/3.jpg)
Epidemiology
• ~25 million experience acute pain from injury or surgery/year
• ~80% of patients experience post-operative pain
▫ <50% report adequate pain relief
▫ 10-50% will develop chronic pain
▫ 2-10% have severe chronic pain
• Pain is the most common symptom experienced by patients in the hospital
3
![Page 4: Acute Pain Management in the Hospital Settingmchodessa.com/wp-content/uploads/2017/10/... · antagonist drug or abrupt dose reduction or discontinuation Physical dependence •A behavioral](https://reader034.vdocument.in/reader034/viewer/2022050122/5f52ade31e7d9169ce21b016/html5/thumbnails/4.jpg)
Significance
• Chronic pain• Prolonged rehabilitation• Reduction in quality of life• Negative social/psychological effects
Inadequate acute pain treatment
• Reduction in hospital length of stay and costs• Increase patient satisfaction
Appropriate pain management
4
![Page 5: Acute Pain Management in the Hospital Settingmchodessa.com/wp-content/uploads/2017/10/... · antagonist drug or abrupt dose reduction or discontinuation Physical dependence •A behavioral](https://reader034.vdocument.in/reader034/viewer/2022050122/5f52ade31e7d9169ce21b016/html5/thumbnails/5.jpg)
Patient Case: Maria, 65 yo F
• CC: ▫ Increasing abdominal pain
• PMH: ▫ Stage 3 colon cancer, CKD Stage 3, seizure hx
• Drug allergies: ▫ Morphine
• Home pain regimen:▫ Oxycodone/acetaminophen 10-325 mg q6h
• Inpatient pain regimen: Pain score 7/10▫ Oxycodone/acetaminophen 10-325 mg q6h
▫ Acetaminophen 650 mg PO q4h prn mild pain (x0 doses)
▫ Morphine 2 mg IV q4h prn mod-severe pain (x6 doses)
5
![Page 6: Acute Pain Management in the Hospital Settingmchodessa.com/wp-content/uploads/2017/10/... · antagonist drug or abrupt dose reduction or discontinuation Physical dependence •A behavioral](https://reader034.vdocument.in/reader034/viewer/2022050122/5f52ade31e7d9169ce21b016/html5/thumbnails/6.jpg)
Types of Pain
Acute vs. chronic
Musculoskeletal
Nociceptive
Somatic
Visceral
Neuropathic
Inflammatory
6
![Page 7: Acute Pain Management in the Hospital Settingmchodessa.com/wp-content/uploads/2017/10/... · antagonist drug or abrupt dose reduction or discontinuation Physical dependence •A behavioral](https://reader034.vdocument.in/reader034/viewer/2022050122/5f52ade31e7d9169ce21b016/html5/thumbnails/7.jpg)
Pathophysiology
Stimulation
Transmission
Modulation
Perception
7
![Page 8: Acute Pain Management in the Hospital Settingmchodessa.com/wp-content/uploads/2017/10/... · antagonist drug or abrupt dose reduction or discontinuation Physical dependence •A behavioral](https://reader034.vdocument.in/reader034/viewer/2022050122/5f52ade31e7d9169ce21b016/html5/thumbnails/8.jpg)
Tolerance, Physical Dependence,
Addiction, Pseudoaddiction
• Diminishing of drug effect over time as a consequence of exposure to the drug
Tolerance
• The occurrence of an abstinence syndrome following administration of an antagonist drug or abrupt dose reduction or discontinuation
Physical dependence
• A behavioral pattern characterized by loss of control over drug use, compulsive drug use, and continued use of a drug despite harm
Addiction
• Behavior that may suggest addiction, but is actually a reflection of unrelieved pain
Pseudoaddiction
8
![Page 9: Acute Pain Management in the Hospital Settingmchodessa.com/wp-content/uploads/2017/10/... · antagonist drug or abrupt dose reduction or discontinuation Physical dependence •A behavioral](https://reader034.vdocument.in/reader034/viewer/2022050122/5f52ade31e7d9169ce21b016/html5/thumbnails/9.jpg)
Multimodal Approach
Patient Education (realistic goals)
Pharmacological Treatment
(NSAIDs, opioids, adjuvants)
PhysicialTherapy
Interventional Therapy
(surgical)
Psychologoical(behavioral, counseling)
9
![Page 10: Acute Pain Management in the Hospital Settingmchodessa.com/wp-content/uploads/2017/10/... · antagonist drug or abrupt dose reduction or discontinuation Physical dependence •A behavioral](https://reader034.vdocument.in/reader034/viewer/2022050122/5f52ade31e7d9169ce21b016/html5/thumbnails/10.jpg)
WHO 3-Step Pain Ladder
Moderate-Severe
Strong Opioid/Nonopioid ±
Adjuvants
Mild-Moderate
Weak Opioid/ Nonopioid ±
Adjuvants
Mild
Nonopioid± Adjuvants
Nonopioid analgesics:AcetaminophenNSAIDsAspirinSalicylates
Weak opioids:CodeineHydrocodoneTramadol
Strong opioids:Morphine*Hydromorphone*FentanylMethadoneOxycodone*(*can be used for mild-moderate pain at low doses)
10
![Page 11: Acute Pain Management in the Hospital Settingmchodessa.com/wp-content/uploads/2017/10/... · antagonist drug or abrupt dose reduction or discontinuation Physical dependence •A behavioral](https://reader034.vdocument.in/reader034/viewer/2022050122/5f52ade31e7d9169ce21b016/html5/thumbnails/11.jpg)
Patient Assessment
Patient’s pain and functional goals
Effects of pain on physical, emotional, and psychological function
What causes or increases pain?
What relieves the pain?
Description of pain
11
![Page 12: Acute Pain Management in the Hospital Settingmchodessa.com/wp-content/uploads/2017/10/... · antagonist drug or abrupt dose reduction or discontinuation Physical dependence •A behavioral](https://reader034.vdocument.in/reader034/viewer/2022050122/5f52ade31e7d9169ce21b016/html5/thumbnails/12.jpg)
True Allergy vs. Pseudoallergy
Phenanthrenes
• Morphine• Codeine• Hydromorphone• Oxycodone• Hydrocodone
Phenylpiperidine
• Meperidine• Fentanyl
Phenylheptane
• Methadone
Classifications of Opioids
Switch to another opioid class (low cross sensitivity)Switch to a higher potency opioid
12
![Page 13: Acute Pain Management in the Hospital Settingmchodessa.com/wp-content/uploads/2017/10/... · antagonist drug or abrupt dose reduction or discontinuation Physical dependence •A behavioral](https://reader034.vdocument.in/reader034/viewer/2022050122/5f52ade31e7d9169ce21b016/html5/thumbnails/13.jpg)
Opioid-Naïve vs. Opioid-Tolerant
Opioid-tolerant patient: Use of the following for at least 7 days or longer -
60 mg oral morphine/day
25 mcg transdermal fentanyl/hr
30 mg oral oxycodone/day
8 mg oral hydromorphone/day
25 mg oral oxymorphone/day
An equianalgesic dose of another opioid
13
![Page 14: Acute Pain Management in the Hospital Settingmchodessa.com/wp-content/uploads/2017/10/... · antagonist drug or abrupt dose reduction or discontinuation Physical dependence •A behavioral](https://reader034.vdocument.in/reader034/viewer/2022050122/5f52ade31e7d9169ce21b016/html5/thumbnails/14.jpg)
Opioid Naïve: Dose Initiation
• Acute, severe pain:
▫ Morphine
2-5 mg IV q4h PRN
Elderly – start low, go slow
▫ Hydromorphone
0.5-1 mg IV q4h PRN
▫ Oxycodone
2.5-7.5 mg q4h PRN
14
![Page 15: Acute Pain Management in the Hospital Settingmchodessa.com/wp-content/uploads/2017/10/... · antagonist drug or abrupt dose reduction or discontinuation Physical dependence •A behavioral](https://reader034.vdocument.in/reader034/viewer/2022050122/5f52ade31e7d9169ce21b016/html5/thumbnails/15.jpg)
Scheduled Regimens
• Chronic pain:
▫ Long-acting opioid + short-acting opioid
• Breakthrough pain
▫ 10% of total daily dose (24-hr) -> every hr PRN
15
![Page 16: Acute Pain Management in the Hospital Settingmchodessa.com/wp-content/uploads/2017/10/... · antagonist drug or abrupt dose reduction or discontinuation Physical dependence •A behavioral](https://reader034.vdocument.in/reader034/viewer/2022050122/5f52ade31e7d9169ce21b016/html5/thumbnails/16.jpg)
Incomplete Cross-Tolerance
Mu opioids bind to mu receptors
• Mu opioids produce subtle differences in pharmacological response based on activation profiles of mu receptor sybtypes
Many mu receptor subtypes:
• Inter-patient variability in response to mu opioids• Incomplete cross-tolerance among mu opioids• Importance of calculating % dose reductions when
switching opioids
Explains:
16
![Page 17: Acute Pain Management in the Hospital Settingmchodessa.com/wp-content/uploads/2017/10/... · antagonist drug or abrupt dose reduction or discontinuation Physical dependence •A behavioral](https://reader034.vdocument.in/reader034/viewer/2022050122/5f52ade31e7d9169ce21b016/html5/thumbnails/17.jpg)
Opioid Rotation
Reduce equianalgesic dose by 25-50%*
Current opioid
regimen
Current pain
control
Elderly/ medically
frail
Same drug, different
route
Calculate equianalgesic dose of new opioid
*75-90% reduction for methadone
17
![Page 18: Acute Pain Management in the Hospital Settingmchodessa.com/wp-content/uploads/2017/10/... · antagonist drug or abrupt dose reduction or discontinuation Physical dependence •A behavioral](https://reader034.vdocument.in/reader034/viewer/2022050122/5f52ade31e7d9169ce21b016/html5/thumbnails/18.jpg)
Equianalgesic Opioid Dosing
Drug Parenteral (mg) Oral (mg)
Morphine 10 30
Hydromorphone 1.5 7.5
Oxycodone N/A 20
Oxymorphone 1 10
Hydrocodone N/A 30
Codeine 130 200
Meperidine 75 300
Fentanyl 0.1 N/A
18
![Page 19: Acute Pain Management in the Hospital Settingmchodessa.com/wp-content/uploads/2017/10/... · antagonist drug or abrupt dose reduction or discontinuation Physical dependence •A behavioral](https://reader034.vdocument.in/reader034/viewer/2022050122/5f52ade31e7d9169ce21b016/html5/thumbnails/19.jpg)
Hepatic Impairment: Opioid Metabolism
Opioid Extraction Ratio
Codeine 0.52
Fentanyl 0.80-1.0
Hydromorphone 0.51
Methadone <0.30
Meperidine 0.52
Morphine 0.76
Pentazocine 0.80
Metabolism Opioid Affected
CYP3A4 (Phase 1) Fentanyl, oxycodone, tramadol
CYP2D6 (Phase 1) Codeine, hydrocodone
Glucuronidation (Phase II) Hydromorphone, oxymorphone, morphine
19
![Page 20: Acute Pain Management in the Hospital Settingmchodessa.com/wp-content/uploads/2017/10/... · antagonist drug or abrupt dose reduction or discontinuation Physical dependence •A behavioral](https://reader034.vdocument.in/reader034/viewer/2022050122/5f52ade31e7d9169ce21b016/html5/thumbnails/20.jpg)
Hepatic Impairment: Recommendations
Opioid Recommendation
Codeine Not recommended; prodrug, reduced conversion to active metabolite -> poor analgesic effect
Fentanyl 99% metabolized in liver; careful monitoring
Hydrocodone Use with caution; monitor for overdose due to reduced metabolism of parent compoound
Hydromorphone Use with caution; undergoes phase II reaction and intermediate extraction ratio
Methadone Use with caution; risk of accumulation due to increased free drug
Meperidine Not recommended; toxic metabolite, normeperidine, may accumulate
Morphine Use with caution; monitor for overdose due to high extraction ratio
Oxycodone Use with caution; reduce dose by 25-50%
Oxymorphone Contraindicated in moderate-severe hepatic impairment
Tramadol Not recommended
20
![Page 21: Acute Pain Management in the Hospital Settingmchodessa.com/wp-content/uploads/2017/10/... · antagonist drug or abrupt dose reduction or discontinuation Physical dependence •A behavioral](https://reader034.vdocument.in/reader034/viewer/2022050122/5f52ade31e7d9169ce21b016/html5/thumbnails/21.jpg)
Renal Impairment: Dosing
GFR (mL/min)
Morphine Hydromorphone
Oxycodone Methadone Fentanyl
>50 N/A 0-50% N/A N/A N/A
10-50 50-75% 50% 50% N/A 0-25%
<10 Not recommended
25% Not recommended
0-25% 50%
% Dose Reduction
21
![Page 22: Acute Pain Management in the Hospital Settingmchodessa.com/wp-content/uploads/2017/10/... · antagonist drug or abrupt dose reduction or discontinuation Physical dependence •A behavioral](https://reader034.vdocument.in/reader034/viewer/2022050122/5f52ade31e7d9169ce21b016/html5/thumbnails/22.jpg)
Renal Impairment: Recommendations
Opioid Recommendation
Codeine Not recommended due to accumulation
Fentanyl Appears safe; adjust dose if needed
Hydrocodone/oxycodone Use with caution; adjust dose if needed
Hydromorphone Use with caution; adjust dose if needed
Methadone Appears safe; adjust dose if needed
Meperidine Not recommended due to metabolites
Morphine Not recommended due to metabolites
Tramadol Not recommended
22
![Page 23: Acute Pain Management in the Hospital Settingmchodessa.com/wp-content/uploads/2017/10/... · antagonist drug or abrupt dose reduction or discontinuation Physical dependence •A behavioral](https://reader034.vdocument.in/reader034/viewer/2022050122/5f52ade31e7d9169ce21b016/html5/thumbnails/23.jpg)
Management of Adverse Effects
• Non-IgE mediated mast cell binding and histamine release• Antihistamines, anticholinergics
Pruritis
• Stimulation of chemoreceptor trigger zone (CTZ)• Antipsychotics, metoclopramide, serotonin antagonists
N/V
• Stimulates mu receptors in GI tract causing slowed GI motility• Scheduled prophylaxis bowel regimen (doc/senna, PEG, fluids,
fiber)Constipation
• Caution in patients with chronic lung disease (COPD, asthma)• Incidence is very low and associated with overdose
Respiratory depression
• CNS depressants (benzodiazepines, alcohol use)• Stimulants (methylphenidate)
Sedation
23
![Page 24: Acute Pain Management in the Hospital Settingmchodessa.com/wp-content/uploads/2017/10/... · antagonist drug or abrupt dose reduction or discontinuation Physical dependence •A behavioral](https://reader034.vdocument.in/reader034/viewer/2022050122/5f52ade31e7d9169ce21b016/html5/thumbnails/24.jpg)
Medication Pearls
24
![Page 25: Acute Pain Management in the Hospital Settingmchodessa.com/wp-content/uploads/2017/10/... · antagonist drug or abrupt dose reduction or discontinuation Physical dependence •A behavioral](https://reader034.vdocument.in/reader034/viewer/2022050122/5f52ade31e7d9169ce21b016/html5/thumbnails/25.jpg)
Acetaminophen
• Analgesic effects only (not anti-inflammatory)
• Maximum dose <4g/day
• Alcohol use increases risk for hepatic toxicity
• Oral – onset <1 hr
• Rectal – slow, unpredictable absorption
• IV – $$$
25
![Page 26: Acute Pain Management in the Hospital Settingmchodessa.com/wp-content/uploads/2017/10/... · antagonist drug or abrupt dose reduction or discontinuation Physical dependence •A behavioral](https://reader034.vdocument.in/reader034/viewer/2022050122/5f52ade31e7d9169ce21b016/html5/thumbnails/26.jpg)
NSAIDs
• Use:
▫ Mild-moderate-severe pain, cancer-related bone pain
• Avoid combining NSAIDs (additive toxicities)
• Increase to maximum dose change if ineffective
• Ketorolac:
▫ IV/IM; short term use only (max = 5 days)
• Add GI prophylaxis:
▫ Assess CVD risk vs. GI bleed risk
• A/E: renal toxicity
▫ D/c NSAID if BUN or Cr doubles
26
![Page 27: Acute Pain Management in the Hospital Settingmchodessa.com/wp-content/uploads/2017/10/... · antagonist drug or abrupt dose reduction or discontinuation Physical dependence •A behavioral](https://reader034.vdocument.in/reader034/viewer/2022050122/5f52ade31e7d9169ce21b016/html5/thumbnails/27.jpg)
Adjuvant Analgesics
• Use
▫ Chronic pain (inflammatory, neuropathic)
• Anticonvulsants
▫ Decrease neuronal excitability
• TCAs and SNRIs
▫ Enhance pain inhibition
• Topical anesthetics
▫ Decrease nerve stimulation
27
![Page 28: Acute Pain Management in the Hospital Settingmchodessa.com/wp-content/uploads/2017/10/... · antagonist drug or abrupt dose reduction or discontinuation Physical dependence •A behavioral](https://reader034.vdocument.in/reader034/viewer/2022050122/5f52ade31e7d9169ce21b016/html5/thumbnails/28.jpg)
Codeine
• Commonly used combined
▫ Mild-mod pain
• FDA BW:
▫ Risk of death in CYP450-2D6 rapid metabolizers
• Poor analgesic potency
• A/E:
▫ Increased nausea and constipation
• Active metabolite:
▫ Morphine
28
![Page 29: Acute Pain Management in the Hospital Settingmchodessa.com/wp-content/uploads/2017/10/... · antagonist drug or abrupt dose reduction or discontinuation Physical dependence •A behavioral](https://reader034.vdocument.in/reader034/viewer/2022050122/5f52ade31e7d9169ce21b016/html5/thumbnails/29.jpg)
Hydrocodone
• Commonly used in combination
• A/E
▫ Nausea, constipation (less than codeine)
• Reduce dose in severe hepatic impairment
• Metabolites accumulate in renal insufficiency
29
![Page 30: Acute Pain Management in the Hospital Settingmchodessa.com/wp-content/uploads/2017/10/... · antagonist drug or abrupt dose reduction or discontinuation Physical dependence •A behavioral](https://reader034.vdocument.in/reader034/viewer/2022050122/5f52ade31e7d9169ce21b016/html5/thumbnails/30.jpg)
Tramadol
• MOA▫ Binds to mu-opioid receptors▫ Inhibits serotonin and norepinephrine reuptake
• Use▫ Mod-severe pain▫ Chronic pain, neuropathic pain
• A/E▫ N/V
• Serotonin syndrome and seizure risk - (max 400 mg/day)▫ Use with other drugs that reduce seizure threshold▫ Hx of seizures▫ Reduce dose in renal impairment and elderly
30
![Page 31: Acute Pain Management in the Hospital Settingmchodessa.com/wp-content/uploads/2017/10/... · antagonist drug or abrupt dose reduction or discontinuation Physical dependence •A behavioral](https://reader034.vdocument.in/reader034/viewer/2022050122/5f52ade31e7d9169ce21b016/html5/thumbnails/31.jpg)
Morphine
• Gold standard for conversions• Drug of choice
▫ Severe pain, ACS pain (decrease in myocardial oxygen demand)
• Multiple dosage forms▫ PO, IV/IM/SC, Spinal IT, epidural, SL, rectal
• A/E▫ Orthostatic hypotension, pruritis
• Renal impairment▫ M3G metabolite accumulates in renal impairment
neurotoxicity, seizures• Hepatic impairment
▫ Lengthen frequency in administration
31
![Page 32: Acute Pain Management in the Hospital Settingmchodessa.com/wp-content/uploads/2017/10/... · antagonist drug or abrupt dose reduction or discontinuation Physical dependence •A behavioral](https://reader034.vdocument.in/reader034/viewer/2022050122/5f52ade31e7d9169ce21b016/html5/thumbnails/32.jpg)
Oxycodone
• Useful
▫ Moderate-severe pain
▫ IR or ER for acute or persistent pain
▫ Available in combination
• >potent than morphine
• PO only
32
![Page 33: Acute Pain Management in the Hospital Settingmchodessa.com/wp-content/uploads/2017/10/... · antagonist drug or abrupt dose reduction or discontinuation Physical dependence •A behavioral](https://reader034.vdocument.in/reader034/viewer/2022050122/5f52ade31e7d9169ce21b016/html5/thumbnails/33.jpg)
Hydromorphone
• Compared to morphine
▫ >Potent than morphine
▫ Better oral absorption
▫ Similar pharmacological profile
• Renal impairment
▫ Toxic metabolite hydromorphone-3-glucuronide (H3G)
33
![Page 34: Acute Pain Management in the Hospital Settingmchodessa.com/wp-content/uploads/2017/10/... · antagonist drug or abrupt dose reduction or discontinuation Physical dependence •A behavioral](https://reader034.vdocument.in/reader034/viewer/2022050122/5f52ade31e7d9169ce21b016/html5/thumbnails/34.jpg)
Oxymorphone
• > potent than morphine, oxycodone
• Available in
▫ PO, rectal, IV
• Poor oral bioavailability (~10%)
• Administration
▫ Take on empty stomach
• Good option for patients complaining of pruritisreaction from morphine
▫ Higher potency and reduced histamine release
34
![Page 35: Acute Pain Management in the Hospital Settingmchodessa.com/wp-content/uploads/2017/10/... · antagonist drug or abrupt dose reduction or discontinuation Physical dependence •A behavioral](https://reader034.vdocument.in/reader034/viewer/2022050122/5f52ade31e7d9169ce21b016/html5/thumbnails/35.jpg)
Fentanyl
• High potency, short acting▫ 10 mg morphine IV q4h ~ 100 mcg fentanyl IV q1h
• Avoid▫ Opioid naïve patients
• Useful▫ Around the clock pain, bowel obstruction, severe
opioid-induced constipation or pruritis• Available
▫ Patch - 72h duration, chronic pain use only 12-24 hrs for full onset, up to 6 days to reach steady state Good alternative for pts on stable regimens
▫ IV, IT, SL
35
![Page 36: Acute Pain Management in the Hospital Settingmchodessa.com/wp-content/uploads/2017/10/... · antagonist drug or abrupt dose reduction or discontinuation Physical dependence •A behavioral](https://reader034.vdocument.in/reader034/viewer/2022050122/5f52ade31e7d9169ce21b016/html5/thumbnails/36.jpg)
Methadone
• Pearls▫ Oral efficacy, extended duration of action, low cost▫ Prolongs QT – risk of torsades de pointes▫ Unpredictable half life, possible excessive sedation, difficulty in titration
• MOA:▫ Mu and Kappa opioid agonist effects▫ NMDA antagonist▫ SNRI
• Useful▫ Neuropathic and chronic pain▫ Poor pain control with opioids▫ Renal dysfunction (no active metabolites)▫ Less constipating
• Available▫ PO, IV, IM, SL
36
![Page 37: Acute Pain Management in the Hospital Settingmchodessa.com/wp-content/uploads/2017/10/... · antagonist drug or abrupt dose reduction or discontinuation Physical dependence •A behavioral](https://reader034.vdocument.in/reader034/viewer/2022050122/5f52ade31e7d9169ce21b016/html5/thumbnails/37.jpg)
Meperidine
• Neurotoxicity, seizures = Max (300 mg/day IV)
▫ Higher risk in elderly or renal impairment –accumulation of toxic metabolite, normeperidine
• Weak analgesic effect ~ 10-fold < potent than morphine
▫ Short duration of action - more frequent and higher doses for pain relief
• Not recommended for long term use
37
![Page 38: Acute Pain Management in the Hospital Settingmchodessa.com/wp-content/uploads/2017/10/... · antagonist drug or abrupt dose reduction or discontinuation Physical dependence •A behavioral](https://reader034.vdocument.in/reader034/viewer/2022050122/5f52ade31e7d9169ce21b016/html5/thumbnails/38.jpg)
Buprenorphine
• Indication: treatment for opioid dependency
38
![Page 39: Acute Pain Management in the Hospital Settingmchodessa.com/wp-content/uploads/2017/10/... · antagonist drug or abrupt dose reduction or discontinuation Physical dependence •A behavioral](https://reader034.vdocument.in/reader034/viewer/2022050122/5f52ade31e7d9169ce21b016/html5/thumbnails/39.jpg)
Naloxone
• MOA
▫ Pure opioid antagonist
▫ Binds competitively to opioid receptors w/o analgesic effects
• Use
▫ Opioid reversal agent
• Dose
▫ 0.04 – 0.4 mg
39
![Page 40: Acute Pain Management in the Hospital Settingmchodessa.com/wp-content/uploads/2017/10/... · antagonist drug or abrupt dose reduction or discontinuation Physical dependence •A behavioral](https://reader034.vdocument.in/reader034/viewer/2022050122/5f52ade31e7d9169ce21b016/html5/thumbnails/40.jpg)
Patient Case: Maria, 65 yo F
• CC: ▫ Increasing abdominal pain
• PMH: ▫ Stage 3 colon cancer, CKD Stage 3, seizure hx
• Drug allergies: ▫ Morphine
• Home pain regimen:▫ Oxycodone/acetaminophen 10-325mg q6h
• Inpatient pain regimen: ▫ Oxycodone/acetaminophen 10-325mg q6h▫ Acetaminophen 650 mg PO q4h prn mild pain (x0 doses)▫ Morphine 2.5 mg PO q4h prn mod-severe pain (x6 doses)
• Pain score 7/10
40
![Page 41: Acute Pain Management in the Hospital Settingmchodessa.com/wp-content/uploads/2017/10/... · antagonist drug or abrupt dose reduction or discontinuation Physical dependence •A behavioral](https://reader034.vdocument.in/reader034/viewer/2022050122/5f52ade31e7d9169ce21b016/html5/thumbnails/41.jpg)
Patient Case: Maria, 65 yo F
• What are some patient-specific considerations?
• What are her preferred treatment options?
• What is your recommendation?
• When to consider a long-acting agent?
41
![Page 42: Acute Pain Management in the Hospital Settingmchodessa.com/wp-content/uploads/2017/10/... · antagonist drug or abrupt dose reduction or discontinuation Physical dependence •A behavioral](https://reader034.vdocument.in/reader034/viewer/2022050122/5f52ade31e7d9169ce21b016/html5/thumbnails/42.jpg)
Patient Case: Maria, 65 yo F
• Patient specific factors▫ Age, hepatic and renal impairment, hx of seizures,
morphine allergy, opioid-tolerant• Preferred treatment options?
▫ Switching morphine -> hydromorphone▫ Switching to fentanyl▫ Increasing oxycodone-apap dose
• Not recommended▫ Meperidine and tramadol (hx of seizures, renal
impairment)• When to consider a long-acting agent?
▫ If patient has a chronic pain condition▫ Had ~3 or more prn doses for severe pain
42
![Page 43: Acute Pain Management in the Hospital Settingmchodessa.com/wp-content/uploads/2017/10/... · antagonist drug or abrupt dose reduction or discontinuation Physical dependence •A behavioral](https://reader034.vdocument.in/reader034/viewer/2022050122/5f52ade31e7d9169ce21b016/html5/thumbnails/43.jpg)
Questions?
43
![Page 44: Acute Pain Management in the Hospital Settingmchodessa.com/wp-content/uploads/2017/10/... · antagonist drug or abrupt dose reduction or discontinuation Physical dependence •A behavioral](https://reader034.vdocument.in/reader034/viewer/2022050122/5f52ade31e7d9169ce21b016/html5/thumbnails/44.jpg)
References1. Baumann TJ, Strickland J. Pain Management. In: Dipiro, JT, Talbert RL, Yee, GC, eds.
Pharmacotherapy: A Pathophysiologic Approach. New York: McGraw-Hill; 2008: 989-1003.
2. American Pain Society. Guideline for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain. http://americanpainsociety.org/uploads/education/guidelines/chronic-opioid-therapy-cncp.pdf (accessed on 31 Aug 2017).
3. World Health Organization. WHO's cancer pain ladder for adults. http://www.who.int/cancer/palliative/painladder/en/ (accessed on 31 Aug 2017).
4. American Pain Society. Guidelines on the Management of Post-operative Pain. http://www.jpain.org/article/S1526-5900(15)00995-5/pdf (accessed on 31 Aug 2017).
5. US Pharmacist. Opioid Dosing in Renal and Hepatic Impairment. https://www.uspharmacist.com/article/opioid-dosing-in-renal-and-hepatic-impairment (accessed on 31 Aug 2017).
6. Dowell D, Haegerich TM, Chou R et al. CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016. JAMA. 2016; 315(15):1624-45.
7. American Society of Anesthesiologists Task Force. Practice Guidelines for Acute Pain Management in the Perioperative Setting. Anesthesiology. 2012; 116: 248-73.
8. Volkow ND and McLellan T. Opioid Abuse in Chronic Pain – Misconception and Mitigation Strategies. N Engl J Med. 2016; 374: 1253-63.
44